BenevolentAI Investor Conference Presentation Deck
Strategic validation: successful
collaboration with AstraZeneca
Multi-year Target-ID collaboration is
delivering multiple, novel targets for complex
diseases with high unmet need
Separate data environment established to integrate
AstraZeneca's data into a bespoke Knowledge Graph
BenevolentAl and AstraZeneca teams working in close
collaboration to explore, identify and validate targets
Deal structure of upfront license fee, milestone payments
and downstream royalties
Collaboration enables BenevolentAl to enrich its platform via
the data generated as part of the collaboration but also
further validate the use of our Al platform
THERAPEUTIC AREAS
INITIAL DEAL (APRIL 2019)
GO
Chronic kidney
disease (CKD)
AstraZeneca
EXPANSION (DEC 2021)
Heart failure
KEY MILESTONES
CKD
Jan 2021
do
IPF
Dec 2021
3
To date, five novel targets have been validated &
selected for AstraZeneca's portfolio
IPF
May 2022
Idiopathic
pulmonary
fibrosis (IPF)
Systemic lupus
erythematosus
CKD
Oct 2022
IPF
Oct 2022View entire presentation